Blog & Resources Camargo Blog November 16th, 2009

FDA Approves Xanodyne’s Tranexamic Acid

Xanodyne obtained 505(b)(2) approval for tranexamic acid for use in treating heavy menstrual bleeding (menorrhagia). The RLD is Cyklokapron(R) which is used to treat hemophilia and to reduce the need for replacement therapy during and following tooth extraction. The RLD received orphan approval in 1986. Initially, both tablet and injectable dosage forms were approved but the tablet was discontinued in 2003.

Xanodyne’s product is a modified release tablet. The 505(b)(2) NDA was submitted January 30, 2009. It was granted Priority Review status which specifies a 6-month review cycle. However, it received FDA approval in 9.5 months.

Tranexaminc acid has been used for many years for menorrhagia, with numerous controlled trials. Xanodyne capitalized on this body of knowledge and also made the formulation change to improve market position.

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.

Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.

9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights